These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 7679609

  • 1. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y, Bonavida B, Nio Y, Yoshida O.
    Cancer; 1993 Feb 15; 71(4):1313-21. PubMed ID: 7679609
    [Abstract] [Full Text] [Related]

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA, Custer MC, Rosenberg SA, Lotze MT.
    J Biol Response Mod; 1990 Apr 15; 9(2):113-26. PubMed ID: 2111373
    [Abstract] [Full Text] [Related]

  • 3. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
    Mizutani Y, Yoshida O.
    Int J Urol; 1994 Mar 15; 1(1):49-56. PubMed ID: 7627838
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec 15; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reduction of susceptibility to NK lysis in cisplatin-resistant K562 cell lines.
    Dedoussis G, Menounos P, Papadopoulos N, Gounaris A, Karameris A.
    Anticancer Res; 1998 Dec 15; 18(4C):3081-5. PubMed ID: 9713514
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J, Stone J, Chan WC, Yang ZD, Leatherbury A, Sell KW, Wiktor-Jedrzejczak W, Ahmed-Ansari A.
    Cell Immunol; 1989 Feb 15; 118(2):250-64. PubMed ID: 2491960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.